GLP-1 for Cardiovascular Disease Risk

Cardiovascular disease (narrowed coronary arteries, heart attacks, strokes, failing hearts, poor circulation in the limbs) kills more people than anything else, an estimated 17.9 million a year [11]. Most acute events trace back to atherosclerosis, the slow accumulation of lipid-rich plaque inside arterial walls. What accelerates it is familiar: raised blood pressure, diabetes, poor lipids, smoking, inactivity and excess weight.

Excess weight drives cardiovascular risk independently of the other factors. Visceral fat in particular sustains low-grade inflammation, insulin resistance, an atherogenic lipid pattern and higher blood pressure, each of which speeds plaque formation and stiffens arteries. For decades no weight-loss drug had been shown to reduce cardiovascular events, and several older ones were pulled from the market for causing cardiac harm. Keep that history in mind when reading what follows.

This class changed that record. Developed first for type 2 diabetes, these drugs cut major adverse cardiovascular events across a series of large, well-run outcomes trials. In 2024 the FDA granted Wegovy a dedicated cardiovascular risk-reduction indication on the strength of results in people without diabetes, the first time an obesity medication had earned one.

The earliest signals came from the diabetes outcomes trials the FDA had required since the rosiglitazone episode of 2008. LEADER [2] followed 9,340 people with type 2 diabetes who were at high cardiovascular risk, for a median 3.8 years. Liraglutide 1.8 mg cut a composite of death from cardiovascular causes, non-fatal heart attacks and non-fatal strokes by 13% against placebo. It was the first trial in this class to show superiority. That mattered, because these trials were originally designed only to rule out harm.

SUSTAIN-6 [3] tested weekly semaglutide in 3,297 adults with diabetes at high risk over two years and cut those same events by 26%, with a particularly marked reduction in non-fatal stroke. REWIND [4] then examined dulaglutide in 9,901 patients, deliberately including more people at only moderate risk than earlier trials had, and over a median 5.4 years cut events by 12%. That extended the finding to a much broader slice of the diabetes population.

Pooling seven of these trials, a 2019 meta-analysis [5] put the class effect at a 12% reduction in major events, 12% in cardiovascular death and 16% in fatal or non-fatal stroke among people with diabetes at raised cardiovascular risk, with no significant difference in effect across the patient subgroups it examined. An earlier pooled analysis [6] had reached consistent conclusions.

SELECT [1] is the trial that changed who this applies to. It enrolled 17,604 adults aged 45 and over with established cardiovascular disease (a previous heart attack, stroke or symptomatic peripheral artery disease), a BMI of 27 or above, and no type 2 diabetes. Over a mean follow-up of 39.8 months, semaglutide 2.4 mg cut major events by 20%, with absolute rates of 6.5% against 8.0% on placebo. Two details matter most. The benefit appeared across prespecified subgroups, and the curves separated early, before much difference in body weight had accumulated. That timing implies cardiovascular mechanisms working alongside the weight loss, not only through it. The trial produced the March 2024 approval.

Wegovy holds a separate approval covering the reduction of serious cardiac events, for adults carrying established heart disease alongside either obesity or overweight. The SELECT trial behind it enrolled from a BMI of 27 upward. Established disease means an event or diagnosis already on record: a heart attack, a stroke, or peripheral artery disease with symptoms. Risk factors and family history do not count. This indication comes straight from the SELECT population and is separate from the weight-management one.

Anyone with type 2 diabetes and high cardiovascular risk may qualify instead through the diabetes-labeled products. Semaglutide (injected as Ozempic or taken as the Rybelsus tablet), liraglutide, dulaglutide and tirzepatide (Mounjaro) all carry cardiovascular labeling earned in outcomes trials. The two newest came from SOUL, where oral semaglutide cut major events by 14% against placebo [8], and SURPASS-CVOT, where tirzepatide proved non-inferior to dulaglutide, itself a drug shown to cut events [7]. What the Wegovy indication adds is the group those never reached: people carrying excess weight and known disease who never became diabetic. Primary prevention (risk factors without a prior event) falls outside all of these approvals, and clinicians should say so plainly to patients.

In SELECT the benefit sat on top of everything else: most participants were already on statins, blood-pressure drugs and antiplatelet therapy. These drugs add to guideline-directed treatment, and nobody with established disease should drop a proven cardiovascular medication in favor of one. The side effects match those seen under the obesity indication: nausea, vomiting and stomach discomfort, worst while the dose climbs and easing after.

Heart failure with reduced ejection fraction is a different and much weaker case; dedicated trials are still running, and what randomized evidence exists in that phenotype is not encouraging. Recent acute coronary syndrome, heart failure that has decompensated, or a serious rhythm disturbance all mean starting only in close coordination with a cardiologist. Diet, activity, stopping smoking and limiting alcohol remain the foundation, and none of this replaces them. Cost and access are real obstacles, particularly at the 2.4 mg dose that SELECT used.